lixia chen
Shenyang Pharmaceutical University
Shenyang, China
Review Editor
Anti-Cancer Drugs
Shenyang Pharmaceutical University
Shenyang, China
Review Editor
Anti-Cancer Drugs
C4 Therapeutics
Watertown, United States
Review Editor
Technologies and Strategies to Enable Drug Discovery
Department of Pharmacy, College of Health Sciences, Debre Tabor University
Debre Tabor, Ethiopia
Review Editor
Technologies and Strategies to Enable Drug Discovery
University of North Carolina at Chapel Hill
Chapel Hill, United States
Review Editor
Anti-Cancer Drugs
University of Maryland
Baltimore, United States
Review Editor
Cardiovascular and Hematologic Drugs
Wexner Medical Center, The Ohio State University
Columbus, United States
Review Editor
Dermatologic Drugs
Chobanian & Avedisian School of Medicine, Boston University
Boston, United States
Review Editor
In silico Methods and Artificial Intelligence for Drug Discovery
Novartis Institutes for BioMedical Research
Cambridge, United States
Review Editor
Cardiovascular and Hematologic Drugs
University of Milan
Milan, Italy
Review Editor
Technologies and Strategies to Enable Drug Discovery
Autonomous Metropolitan University Xochimilco Campus
Coyoacán, Mexico
Review Editor
In silico Methods and Artificial Intelligence for Drug Discovery
University of Antwerp
Antwerp, Belgium
Review Editor
Anti-Infective Agents
Flatiron Institute
New York, United States
Review Editor
In silico Methods and Artificial Intelligence for Drug Discovery
National Research Council (CNR)
Roma, Italy
Review Editor
In silico Methods and Artificial Intelligence for Drug Discovery
University of Pisa
Pisa, Italy
Review Editor
Anti-inflammatory and Immunomodulating Agents
Departmet of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences
Toledo, United States
Review Editor
Anti-Cancer Drugs
Sapienza University of Rome
Rome, Italy
Review Editor
Technologies and Strategies to Enable Drug Discovery